X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1595) 1595
Publication (125) 125
Newsletter (32) 32
Book Chapter (24) 24
Book Review (18) 18
Magazine Article (8) 8
Newspaper Article (7) 7
Conference Proceeding (6) 6
Trade Publication Article (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cinacalcet (1016) 1016
humans (1016) 1016
index medicus (707) 707
cinacalcet hydrochloride (674) 674
secondary hyperparathyroidism (626) 626
male (556) 556
female (542) 542
naphthalenes - therapeutic use (509) 509
urology & nephrology (502) 502
middle aged (470) 470
hyperparathyroidism (434) 434
hyperparathyroidism, secondary - drug therapy (410) 410
parathyroid hormone (400) 400
parathyroid hormone - blood (344) 344
adult (308) 308
aged (304) 304
calcium (278) 278
hemodialysis (273) 273
calcium - blood (263) 263
hyperparathyroidism, secondary - etiology (254) 254
renal dialysis (250) 250
kidney failure, chronic - complications (239) 239
parathyroidectomy (236) 236
treatment outcome (227) 227
hemodialysis-patients (213) 213
calcium-sensing receptor (194) 194
vitamin d (191) 191
chronic kidney-disease (184) 184
dialysis (179) 179
kidney failure, chronic - therapy (176) 176
calcimimetic agents - therapeutic use (169) 169
calcimimetics (168) 168
hyperparathyroidism, secondary - blood (157) 157
hypercalcemia (156) 156
parathyroid-hormone (155) 155
transplantation (154) 154
care and treatment (136) 136
dialysis patients (136) 136
naphthalenes - pharmacology (136) 136
mortality (133) 133
animals (130) 130
chronic kidney disease (130) 130
endocrinology & metabolism (130) 130
nephrology (129) 129
phosphorus - blood (125) 125
surgery (125) 125
mineral metabolism (124) 124
stage renal-disease (123) 123
disease (118) 118
medicine & public health (118) 118
kidney diseases (115) 115
pharmacology & pharmacy (115) 115
chronic kidney failure (112) 112
naphthalenes - adverse effects (111) 111
hyperparathyroidism - drug therapy (109) 109
cinacalcet hcl (108) 108
naphthalenes - administration & dosage (107) 107
prospective studies (104) 104
vitamin d - therapeutic use (104) 104
kidney transplantation (103) 103
renal dialysis - adverse effects (101) 101
cardiovascular-disease (100) 100
calcimimetic (99) 99
risk factors (99) 99
vascular calcification (98) 98
time factors (97) 97
cinacalcet hydrochloride - therapeutic use (96) 96
phosphorus (96) 96
calcium - metabolism (95) 95
retrospective studies (95) 95
therapy (95) 95
vitamin-d (94) 94
research (93) 93
hcl (90) 90
calcification (88) 88
hypercalcemia - drug therapy (86) 86
drug therapy (84) 84
medicine, general & internal (84) 84
health aspects (83) 83
analysis (82) 82
primary hyperparathyroidism (82) 82
rats (78) 78
metabolism (76) 76
hypercalcemia - etiology (74) 74
patients (72) 72
receptors, calcium-sensing - metabolism (71) 71
management (70) 70
aged, 80 and over (69) 69
biomarkers - blood (69) 69
kidneys (68) 68
persistent hyperparathyroidism (67) 67
receptors, calcium-sensing - agonists (67) 67
renal insufficiency, chronic - complications (67) 67
drug therapy, combination (65) 65
follow-up studies (64) 64
internal medicine (64) 64
chronic-renal-failure (63) 63
paricalcitol (62) 62
abridged index medicus (61) 61
calcitriol (61) 61
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1416) 1416
Spanish (71) 71
French (47) 47
Japanese (44) 44
German (35) 35
Polish (18) 18
Italian (13) 13
Czech (5) 5
Danish (4) 4
Portuguese (3) 3
Chinese (1) 1
Korean (1) 1
Russian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American Journal of Kidney Diseases, ISSN 0272-6386, 04/2018, Volume 71, Issue 4, pp. 502 - 515
Journal Article
JAMA, ISSN 0098-7484, 01/2017, Volume 317, Issue 2, pp. 156 - 164
IMPORTANCE: Secondary hyperparathyroidism contributes to extraskeletal calcification and is associated with all-cause and cardiovascular mortality. Control is... 
MEDICINE, GENERAL & INTERNAL | CALCIUM-SENSING RECEPTOR | PEPTIDE AGONIST | EVOLVE TRIAL | CARDIOVASCULAR-DISEASE | MINERAL METABOLISM | BONE | CHRONIC KIDNEY-DISEASE | AMG 416 VELCALCETIDE | FGF23 | DIALYSIS | Calcimimetic Agents - administration & dosage | Nausea - chemically induced | Cinacalcet Hydrochloride - pharmacology | Humans | Middle Aged | Calcium - administration & dosage | Male | Cinacalcet Hydrochloride - administration & dosage | Parathyroid Hormone - blood | Peptides - administration & dosage | Calcium - blood | Time Factors | Calcimimetic Agents - pharmacology | Cinacalcet Hydrochloride - adverse effects | Female | Double-Blind Method | Hyperparathyroidism, Secondary - drug therapy | Administration, Oral | Biomarkers - blood | Calcimimetic Agents - adverse effects | Peptides - pharmacology | Kidney Failure, Chronic - therapy | Hyperparathyroidism, Secondary - blood | Vomiting - chemically induced | Fibroblast Growth Factors - blood | Kidney Failure, Chronic - complications | Infusions, Intravenous | Hyperparathyroidism, Secondary - etiology | Peptides - adverse effects | Renal Dialysis | Complications and side effects | Usage | Care and treatment | Parathyroid hormone | Hemodialysis | Dosage and administration | Research | Cinacalcet | Hyperparathyroidism | Patient safety | Endocrine system | Hyperthyroidism | Clinical outcomes
Journal Article
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, ISSN 1720-8386, 02/2019, Volume 42, Issue 2, pp. 243 - 244
Journal Article
Kidney International, ISSN 0085-2538, 05/2019, Volume 95, Issue 5, pp. 1012 - 1014
Calcimimetics are widely used in patients on dialysis to treat secondary hyperparathyroidism. Our current view is that bone effects are only indirect through... 
DIALYSIS PATIENTS | CINACALCET | UROLOGY & NEPHROLOGY
Journal Article
Medicina Clinica, ISSN 0025-7753, 03/2018, Volume 150, Issue 6, pp. 226 - 232
Primary hyperparathyroidism (PHPT) is a common endocrinological process, characterized by chronic elevation of serum concentrations of calcium and parathyroid... 
Cinacalcet | Parathyroid hormone | Primary hyperparathyroidism
Journal Article
Pharmacoepidemiology and Drug Safety, ISSN 1053-8569, 07/2015, Volume 24, Issue 7, pp. 738 - 747
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2012, Volume 367, Issue 26, pp. 2482 - 2494
Journal Article
Clinical Journal of the American Society of Nephrology, ISSN 1555-9041, 03/2016, Volume 11, Issue 3, pp. 539 - 546
Journal Article
Biomedical Chromatography, ISSN 0269-3879, 10/2019, Volume 33, Issue 10, pp. e4631 - n/a
A liquid chromatography–tandem mass spectrometry (LC–MS/MS) method for the determination of cinacalcet in human plasma was developed and validated. This assay... 
pharmacokinetics | cinacalcet | cinacalcet‐d4 | food effect | LC–MS/MS | CHEMISTRY, ANALYTICAL | LC-MS | BIOCHEMISTRY & MOLECULAR BIOLOGY | BIOCHEMICAL RESEARCH METHODS | PHARMACOLOGY & PHARMACY | cinacalcet-d4 | HYDROCHLORIDE | Cinacalcet | Mass spectrometry | Formic acid | Methods | Organic acids | Index Medicus
Journal Article
British Medical Bulletin, ISSN 0007-1420, 03/2019, Volume 129, Issue 1, pp. 53 - 67
Abstract Introduction The presentation of primary hyperparathyroidism (PHPT) has shifted from a disease characterized by renal and skeletal complications to a... 
cinacalcet | primary hyperparathyroidism | conservative management | parathyroidectomy | hypercalcaemia
Journal Article